# A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Source: https://onco.cc/trials/nct06654440/  
OnCo record `nct06654440` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-A2102 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy is a phase 2 interventional study registered as NCT06654440 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 100 participants planned, started 2024-11-15 and due to reach its primary completion in 2025-08-31. Interventions recorded: SHR-A2102 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06654440
- Phase: 2
- Setting: An Open-label, Multicenter Phase II Clinical Study of SHR-A2102 for Injection in the Treatment of Advanced Gynaecological Malignancies
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06654440: https://clinicaltrials.gov/study/NCT06654440

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06654440.json